Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Turner Kufe

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Blood|March 18, 2014
Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell deathLi Yin, Turner Kufe, David Avigan, et al.
International Journal of Oncology|August 3, 2007
Evolution of the human MUC1 oncoproteinSekhar Duraisamy, Turner Kufe, Selvi Ramasamy, et al.
Molecular Pharmacology|May 7, 2010
Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein functionLi Yin, Rehan Ahmad, Michio Kosugi, et al.
Cancer Immunology, Immunotherapy : CII|June 27, 2012
Lenalidomide enhances anti-myeloma cellular immunityKatarina Luptakova, Jacalyn Rosenblatt, Brett Glotzbecker, et al.
Cancer Research|July 23, 2013
MUC1 is a potential target for the treatment of acute myeloid leukemia stem cellsDina Stroopinsky, Jacalyn Rosenblatt, Keisuke Ito, et al.
Journal of Cellular and Molecular Medicine|May 16, 2018
MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanismDina Stroopinsky, Hasan Rajabi, Myrna Nahas, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Blood|March 18, 2014
Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell deathLi Yin, Turner Kufe, David Avigan, et al.
International Journal of Oncology|August 3, 2007
Evolution of the human MUC1 oncoproteinSekhar Duraisamy, Turner Kufe, Selvi Ramasamy, et al.
Molecular Pharmacology|May 7, 2010
Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein functionLi Yin, Rehan Ahmad, Michio Kosugi, et al.
Cancer Immunology, Immunotherapy : CII|June 27, 2012
Lenalidomide enhances anti-myeloma cellular immunityKatarina Luptakova, Jacalyn Rosenblatt, Brett Glotzbecker, et al.
Cancer Research|July 23, 2013
MUC1 is a potential target for the treatment of acute myeloid leukemia stem cellsDina Stroopinsky, Jacalyn Rosenblatt, Keisuke Ito, et al.
Journal of Cellular and Molecular Medicine|May 16, 2018
MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanismDina Stroopinsky, Hasan Rajabi, Myrna Nahas, et al.
Pageof 1